浏览全部资源
扫码关注微信
1.甘肃医学院附属医院药剂科,甘肃 平凉 744000
2.甘肃医学院基础医学院,甘肃 平凉 744000
Published:29 February 2024,
Received:20 May 2023,
Revised:18 January 2024,
扫 描 看 全 文
脱鸣富,唐彩娥,杨鲲等.头孢哌酮舒巴坦致成人凝血功能异常危险因素的系统评价[J].中国药房,2024,35(04):488-493.
TUO Mingfu,TANG Cai’e,YANG Kun,et al.Study on the risk factors of cefoperazone/sulbactam-induced coagulation dysfunction in adult patients: a systematic review[J].ZHONGGUO YAOFANG,2024,35(04):488-493.
脱鸣富,唐彩娥,杨鲲等.头孢哌酮舒巴坦致成人凝血功能异常危险因素的系统评价[J].中国药房,2024,35(04):488-493. DOI: 10.6039/j.issn.1001-0408.2024.04.20.
TUO Mingfu,TANG Cai’e,YANG Kun,et al.Study on the risk factors of cefoperazone/sulbactam-induced coagulation dysfunction in adult patients: a systematic review[J].ZHONGGUO YAOFANG,2024,35(04):488-493. DOI: 10.6039/j.issn.1001-0408.2024.04.20.
目的
2
评价头孢哌酮舒巴坦致成人凝血功能异常的危险因素。
方法
2
检索中国知网、维普网、中国生物医学数据库、万方数据、PubMed、Embase、Cochrane图书馆,收集头孢哌酮舒巴坦致成人凝血功能异常的随机对照试验(RCT)、病例对照研究或队列研究,检索时限为数据库建库至2023年4月30日。筛选文献、提取数据及评价其质量后,采用RevMan 5.3软件进行Meta分析。
结果
2
共纳入13篇文献,其中病例对照研究11篇,队列研究2篇,共计18 387例患者。Meta分析结果显示,凝血功能异常患者中高龄[OR=2.04,95%CI(1.14,3.64),
P
=0.02]、肝功能不全[OR=5.95,95%CI(4.21,8.40),
P
<0.000 01]、肾功能不全[OR=3.51,95%CI(3.04,4.05),
P
<0.001]、低蛋白血症[OR=1.90,95%CI(1.37,2.62),
P
<0.001]、进食欠佳[OR=7.25,95%CI(5.13,10.24),
P
<0.000 01]、头孢哌酮舒巴坦日剂量≥9 g[OR=3.95,95%CI(2.45,6.37),
P
<0.001]、头孢哌酮舒巴坦用药疗程≥10 d[OR=2.43,95%CI(1.81,3.28),
P
<0.001]、联用抗凝药物[OR=2.84,95%CI(2.03,3.97),
P
<0.001]、合并恶性肿瘤[OR=1.60,95%CI(1.20,2.15),
P
<0.001]的构成比均显著高于凝血功能正常患者。
结论
2
高龄、肝肾功能不全、合并恶性肿瘤、低蛋白血症、联用抗凝药物、进食欠佳、日剂量≥9 g和用药疗程≥10 d是头孢哌酮舒巴坦致凝血功能异常的危险因素。
OBJECTIVE
2
To systematically evaluate the risk factors for cefoperazone/sulbactam-induced coagulation dysfunction in adult patients.
METHODS
2
Retrieved from CNKI, VIP, CBM, Wanfang data, PubMed, Embase and Cochrane Library, randomized controlled trial (RCT), case-control study or cohort study about cefoperazone/sulbactam-induced coagulation dysfunction in adult patients were collected from the inception to Apr. 30th, 2023. After literature screening, data extraction and quality evaluation, meta-analysis was carried out by using RevMan 5.3 software.
RESULTS
2
A total of 13 studies were included, among which 11 studies were case-control studies, and 2 studies were cohort studies, involving 18 387 patients in total. Meta-analysis showed that the proportion of advanced age [OR=2.04, 95%CI (1.14, 3.64),
P
=0.02], liver insufficiency [OR=5.95, 95%CI (4.21, 8.40),
P
<0.000 01], renal insufficiency [OR=3.51, 95%CI (3.04, 4.05),
P
<0.001], hypoproteinemia [OR=1.90, 95%CI(1.37, 2.62),
P
<0.001], poor diet [OR=7.25, 95%CI (5.13, 10.24),
P
<0.000 01], daily dose of cefoperazone/sulbactam ≥9 g [OR=3.95, 95%CI (2.45,6.37),
P
<0.001], medication duration of cefoperazone/sulbactam ≥10 d [OR=2.43, 95%CI (1.81, 3.28),
P
<0.001], combined use of anticoagulant drugs [OR=2.84, 95%CI (2.03, 3.97),
P
<0.001], combined with malignant tumor [OR=1.60, 95%CI (1.20, 2.15),
P
<0.001] in patients with abnormal coagulation function were significantly higher than those with normal coagulation function.
CONCLUSIONS
2
Advanced age, liver insufficiency, renal insufficiency, complicated with malignant tumors and hypoalbuminemia, combined use of anticoagulant drugs, poor diet, daily dose ≥9 g, and medication duration≥10 days are risk factors for coagulation dysfunction caused by cefoperazone/sulbactam.
头孢哌酮舒巴坦凝血功能异常危险因素系统评价
coagulation dysfunctionrisk factorssystematic review
WANG W,LIU Y M,YU C,et al. Cefoperazone-sulbactam and risk of coagulation disorders or bleeding:a retrospective cohort study[J]. Expert Opin Drug Saf,2020,19(3):339-347.
CAI Z Y,YANG W,HE Y Y,et al. Cefoperazone/sulbactam-induced abdominal wall hematoma and upper gastrointestinal bleeding:a case report and review of the literature[J]. Drug Saf Case Rep,2016,3(1):2.
朱立华. 实验诊断学[M]. 北京:北京医科大学出版社,2002:144-152.
ZHU L H. Laboratory diagnostics[M]. Beijing:The Peking University Health Science Center Press,2002:144-152.
STANG A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol,2010,25(9):603-605.
HIGGINS J P T,ALTMAN D G,GØTZSCHE P C,et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials[J]. BMJ Clin Res Ed,2011,343:d5928.
KATUKURI G R,MADDALA R N,RAMAMOORTHI K,et al. Cefoperazone induced gastrointestinal bleeding[J]. J Clin Diagn Res,2016,10(8):OD10-OD11.
WANG W,SUN X. Risk of bleeding and coagulation disorders associated with cefoperazone/sulbactam:a real world study based on electronic medical records[J]. Value Health,2018,21:S62.
吴青松,邓清军. 头孢哌酮舒巴坦致凝血异常的危险因素[J]. 中国临床药学杂志,2022,31(4):277-281.
WU Q S,DENG Q J. Risk factors of abnormal coagulation induced by cefoperazone sulbactam[J]. Chin J Clin Pharm,2022,31(4):277-281.
孔超敏,吕彩霞,姚丽霞,等. 老年人静脉应用头孢哌酮舒巴坦钠引起凝血功能异常的危险因素分析[J]. 实用老年医学,2022,36(4):402-404.
KONG C M,LYU C X,YAO L X,et al. Analysis of risk factors of coagulation dysfunction caused by intravenous cefoperazone sulbactam sodium in the elderly[J]. Pract Geriatr,2022,36(4):402-404.
张寒钰,吴迪,王国兴,等. 头孢哌酮/舒巴坦钠引起凝血功能异常的因素分析[J]. 中国病案,2019,20(6):81-84.
ZHANG H Y,WU D,WANG G X,et al. Analysis of clinical factors for coagulation abnormalities induced by cefoperazone-sulbactam in clinical patients[J]. Chin Med Rec,2019,20(6):81-84.
徐露. 头孢哌酮钠舒巴坦钠致凝血功能异常的危险因素及护理[J]. 基因组学与应用生物学,2017,36(3):1195-1198.
XU L. Risk factor analysis and nursing of coagulant func-tion abnormality caused by cefoperazone sodium and sulbactam sodium[J]. Genom Appl Biol,2017,36(3):1195-1198.
戴晓琴,马纯雪,蔡月,等. 头孢哌酮钠舒巴坦钠致凝血功能异常的危险因素分析及护理[J]. 护理学报,2013,20(9):59-61.
DAI X Q,MA C X,CAI Y,et al. Analysis of risk factors of coagulation dysfunction caused by cefoperazone sodium and sulbactam sodium and nursing care of them[J]. J Nurs,2013,20(9):59-61.
朱愿超,梁良,沈姞,等. 头孢哌酮钠舒巴坦钠致凝血功能异常的临床特征和相关因素分析[J]. 中国药学杂志,2022,57(9):741-746.
ZHU Y C,LIANG L,SHEN J,et al. Clinical features and risk factors of coagulation disorders caused by cefoperazone sodium and sulbactam sodium[J]. Chin Pharm J,2022,57(9):741-746.
杜佳丽,焦红梅,孙丹,等. 头孢哌酮/舒巴坦致老年患者凝血功能异常的相关因素分析[J]. 中国临床药理学杂志,2016,32(24):2303-2306.
DU J L,JIAO H M,SUN D,et al. Analysis of relative factors for coagulation abnormalities induced by cefoperazone/sulbactam in elderly patients[J]. Chin J Clin Pharmacol,2016,32(24):2303-2306.
梁河,蒙光义,钟丽球,等. 头孢哌酮钠舒巴坦钠致缺血性脑血管病患者凝血功能异常的影响因素分析[J]. 中国药物警戒,2022,19(1):87-90.
LIANG H,MENG G Y,ZHONG L Q,et al. Influencing factors of coagulation abnormalities induced by cefoperazone sodium and sulbactam sodium in patients with is-chemic cerebrovascular disease[J]. Chin J Pharmacovigil,2022,19(1):87-90.
王钰莹,于建海,段京莉. 头孢哌酮舒巴坦引起凝血功能异常的影响因素分析研究[J]. 中国全科医学,2020,23(增刊1):138-140.
WANG Y Y,YU J H,DUAN J L. Analysis of influencing factors of coagulation dysfunction caused by cefoperazone and sulbactam[J]. Chin Gen Pract,2020,23(Suppl 1):138-140.
石姗平,吴雪,农杰昌,等. 头孢哌酮/舒巴坦致凝血功能异常的影响因素分析[J]. 药物流行病学杂志,2019,28(9):578-580,590.
SHI S P,WU X,NONG J C,et al. Influencing factors of coagulation abnormalities induced by cefoperazone/sulbactam[J]. Chin J Pharmacoepidemiol,2019,28(9):578-580,590.
谭皓文. Logistic回归分析联合ROC曲线对头孢哌酮-舒巴坦钠致凝血功能异常的预测分析[J]. 抗感染药学,2022,19(2):300-304.
TAN H W. Prediction of coagulation disorders caused by cefoperazone/sulbactam with logistic regression analysis combined with ROC curve[J]. Anti Infect Pharm,2022,19(2):300-304.
周华,李光辉,陈佰义,等. 中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J]. 中华医学杂志,2014,94(24):1847-1856.
ZHOU H,LI G H,CHEN B Y,et al. Expert consensus on coping strategies of extended-spectrum β-lactamases producing Enterobacteriaceae infection in China[J]. Natl Med J China,2014,94(24):1847-1856.
中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志,2018,41(6):409-446.
Chinese Medical Education Association Professional Committee of Infection Diseases. Expert consensus on clinical application of pharmacokinetic/pharmacodynamic theory of antibacterial drugs[J]. Chin J Tuberc Respir Dis,2018,41(6):409-446.
CHEN L J,HSIAO F Y,SHEN L J,et al. Use of hypoprothrombinemia-inducing cephalosporins and the risk of hemorrhagic events:a nationwide nested case-control study[J]. PLoS One,2016,11(7):e0158407.
0
Views
9
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution